Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself

Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hin-Fung Yuen, Declan O'Rourke, Muhammad Babur, Brian A Telfer, Huw D Thomas, Patrick Keane, Thiagarajan Nambirajan, Chris Hagan, Joe M O'Sullivan, Christopher Shaw, Kaye J Williams, Nicola J Curtin, David G Hirst, Tracy Robson

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
235 Downloads (Pure)

Fingerprint Dive into the research topics of 'Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds

Agriculture & Biology